OCX-063 is under clinical development by OccuRx and currently in Phase I for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData, Phase I drugs for Non-Proliferative Diabetic Retinopathy (NPDR) have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCX-063’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OCX-063 overview

OCX-063 is under development for the treatment of non-proliferative diabetic retinopathy, proliferative vitreoretinopathy, wet (neovascular / exudative) macular degeneration, diabetic nephropathy, chronic kidney disease and focal segmental glomerulosclerosis (FSGS). It is administered through oral route and formulated in the form of capsule.

OccuRx overview

OccuRx (OccuRx Pty) is a biopharmaceutical company that focuses on the development of innovative therapeutic strategies. The company is headquartered in Melbourne, Victoria, Australia.

For a complete picture of OCX-063’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.